Prescott, AZ. – (August 1, 2012) Imulan BioTherapeutics, LLC (IMULAN) announced they are initiating confirmatory field efficacy and safety studies for their T-cell Receptor (TCR) peptide treatment for dogs with atopic dermatitis. The study is intended to support the approval as a new treatment for dogs with chronic atopic dermatitis and is based on two previous studies showing significant improvements in dogs with allergic dermatitis. IMULAN has produced the first pre-license serials and established a number of clinical trial sites around the country to participate in their trials.
The TCR technology is a new immune-biologic strategy and is covered by several patents, including a recently awarded composition of matter patent. IMULAN holds the global veterinary rights to the TCR technology which includes all pharmaceutical uses in animal health including those for veterinary dermatology. It is estimated that over 5% of dogs in the United States are affected by atopic dermatitis, making it one of the largest companion animal diseases. Compared to existing therapies, the proposed benefits of TCR peptides include a long duration of effect, infrequent dosing, no immunosuppression, no requirement for allergen testing, and a cost effective manufacturing process.
The TCR peptides work by modulating T-helper cell function, a central regulator of allergic skin disease (atopic dermatitis, atopy). In various diseases including atopy, T-helper cell 2 (Th2) responses can become dominant and amplify the allergic response while. The TCR peptides work by modulating Th2 activity to provide a comprehensive approach to allergic skin disease. In addition, the TCR peptide treatment has also been studied in feline stomatitis, canine cardiomyopathy, and canine fungal infections with very encouraging results. IMULAN intends on advancing their work in infectious disease and cardiology in the near term.
About IMULAN: Imulan develops unique, precision immune regulating compounds for veterinary medicine. IMULAN’s primary focus is on immunological strategies to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN has active therapeutic programs for atopic dermatitis and feline stomatitis using their T-Cell receptor peptide platform. For more information about Imulan, please visit www.IMULAN.com.
Contact: Craig Woods DVM, MS, MBA; email@example.com